What Baxter's 8-K filings say: 8 filings, latest Aug 19, 2026
Baxter filed its latest 8-K with the SEC on Aug 19, 2026. It discusses CFO change, governance change and restructuring.
Public (BAX)Medical Equipment Manufacturing10,000+ employeesbaxter.comLinkedIn
- Filed
- Aug 19, 2026
- Filings
- 8
- Signals
- 22
8-K · latest 10
What Baxter's 8-K filings say
- SEC EDGAR
8-K
Filed · 3 signals
Baxter Appoints John Rogers as New CFO, Effective October 1, 2026
Smith+Nephew plcWPP plcJ Sainsbury plcGrab Holdings Limited
- SEC EDGAR
8-K
Filed · 4 signals
Baxter amends credit agreement to increase maximum net leverage ratio through Q3 2027.
Baxter is relaxing its debt covenants for five consecutive quarters, suggesting anticipated pressure on earnings or cash flow.
JPMorgan Chase Bank, N.A.
Baxter increases cash tender offer for senior notes to $600M, up from $500M.
The company is executing a large-scale debt buyback, increasing the offer cap to $600 million.
$600M
Increased aggregate purchase price for cash tender offers of senior notes.
Baxter amends credit agreement to increase leverage ratio and upsizes debt tender offer to $600M.
Baxter is increasing its maximum allowed net leverage ratio for five upcoming quarters, signaling anticipated financial pressure or a strategic capital reallocation.
$600M
Increased aggregate purchase price for cash tender offers for outstanding senior notes.
JPMorgan Chase Bank, N.A.
- SEC EDGAR
8-K
Filed · 4 signals
Interim CFO Anita Zielinski to resign effective September 15, 2026
The departure of the Interim CFO creates a leadership vacuum, forcing an urgent search for a permanent finance leader.
Chief Accounting Officer & Controller Anita Zielinski resigns effective Sept. 15, 2026
The resignation of the Chief Accounting Officer and Controller creates a critical gap in financial reporting and compliance oversight.
- SEC EDGAR
8-K
Filed · 1 signal
Baxter launches $500M cash tender offer to repurchase outstanding senior notes.
The company is actively managing its capital structure by offering to buy back up to $500M of its long-term debt.
$500M
aggregate purchase price for cash tender offers of outstanding senior notes
- SEC EDGAR
8-K
Filed · 3 signals
Baxter restructures from 3 to 2 segments to align cost structure and execution, effective Q2 2026.
Baxter is consolidating its Pharmaceuticals business into its Medical Products & Therapies segment under a new operating model.
Vantive Health LLC
Baxter restructures into two segments under new operating model to improve execution.
Baxter is consolidating from three reportable segments to two as part of a new operating model, impacting financial reporting and cost allocation.
Vantive Health LLC
- SEC EDGAR
8-K
Filed · 1 signal
The company's new severance plan confirms Anita Zielinski is serving as Interim CFO.
Showing 10 of 22 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Baxter with the Signal API
One POST /v1/companies/enrich call with baxter.com returns Baxter 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"baxter.com","signal_types":["sec-8k"],"limit":20}'Same industry
8-K at related companies
Questions about Baxter 8-K
When did Baxter file its latest 8-K?
What did Baxter disclose in its latest 8-K?
Where can I read Baxter's 8-K filing?
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .